Xhance (fluticasone propionate) is a prescription nasal spray. It’s used to treat nasal and sinus inflammation with or without nasal polyps in adults. This drug can interact with other ...

Optinose (NASDAQ: OPTN) has announced preliminary unaudited net product revenue of $22.4 million for the fourth quarter of ...

A saline nasal spray is a mixture of sterile water and 0.9% sodium chloride (salt) that you can spray up your nostrils to flush out pollen, dust, and other allergens from your nasal passages (the ...

It is important to understand how tanning nasal sprays work, their possible side effects, and safer ways to achieve a tan. Tanning nasal spray contains what is known as melanotan II, an ingredient ...

In light of these financial results, OptiNose revised its 2024 sales forecast for Xhance, its nasal spray treatment, to a range of $75 million to $79 million. Despite this adjustment, the company ...

In light of these financial results, OptiNose revised its 2024 sales forecast for Xhance, its nasal spray treatment, to a range of $75 million to $79 million. Despite this adjustment, the company ...

has seen its profile rise with the development of XHANCE, a corticosteroid drug-device combination nasal spray. XHANCE is the first and only approved treatment for patients with chronic ...

Optinose reports preliminary fourth quarter 2024 XHANCE revenue of $22.4 million, indicating sustained prescription growth. Full results expected in March. Optinose, a pharmaceutical company ...

(MENAFN- GlobeNewsWire - Nasdaq) Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20% YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE ...

(RTTNews) - Optinose, Inc. (OPTN), a pharmaceutical company focused on ear, nose and throat or ENT and allergy, announced Wednesday preliminary XHANCE (fluticasone propionate) net product revenue ...